insights_auto
Miks on 4142 langenud? 3,31%?
Uurige põhjalikumaltchevron_right
4142:TPE
Adimmune Corp
16,05Â NT$
arrow_downward
−3,31%(−0,55) 1 p
6. nov, 10:08:42 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Ava
16,05Â NT$
Kõrge
16,10Â NT$
Madal
15,65Â NT$
Turu kapit.
6,92Â mld
Keskm. maht
1,08Â mln
Maht
1,29Â mln
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
15,65Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Ava
16,05Â NT$
Kõrge
16,10Â NT$
Madal
15,65Â NT$
Turu kapit.
6,92Â mld
Keskm. maht
1,08Â mln
Maht
1,29Â mln
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
15,65Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
Yahoo Finance
·
42 minuti eest
The Nasdaq Composite Just Shattered Its Single-Session Point-Loss Record: 3 Reasons These Elevator-Down Moves May Be Just Beginning
seMissourian
·
18 minuti eest
Brutal sell-off for AI stocks sends Wall Street reeling, S&P 500 tumbles 4.4%
Reuters Connect
·
20 minuti eest
Licensable picture: China: US Stocks Declined
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta